Get the Stockscreener App
24.00
15.61%
3.24
After Hours:
23.00
-1.00
-4.17%
Neurogene Inc stock is traded at $24.00, with a volume of 370.08K.
It is up +15.61% in the last 24 hours and up +11.58% over the past month.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
See More
Previous Close:
$20.76
Open:
$20.94
24h Volume:
370.08K
Relative Volume:
2.36
Market Cap:
$373.78M
Revenue:
$925.00K
Net Income/Loss:
$-90.35M
P/E Ratio:
-5.0946
EPS:
-4.7109
Net Cash Flow:
$-78.52M
1W Performance:
+11.06%
1M Performance:
+11.58%
6M Performance:
-30.17%
1Y Performance:
+111.27%
1-Day Range:
$20.94
$24.85
1-Week Range:
$19.13
$24.85
52-Week Range:
$10.46
$37.27
Neurogene Inc Stock (NGNE) Company Profile
Name
Neurogene Inc
Sector
Industry
Phone
(877) 237-5020
Address
535 W 24TH STREET, NEW YORK
Compare NGNE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
24.00 | 323.32M | 925.00K | -90.35M | -78.52M | -4.7109 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Craig Hallum | Buy |
| May-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Mar-21-24 | Initiated | William Blair | Outperform |
| Jan-08-24 | Initiated | H.C. Wainwright | Buy |
| Jan-05-24 | Initiated | Stifel | Buy |
| Jan-04-24 | Initiated | TD Cowen | Outperform |
View All
Neurogene Inc Stock (NGNE) Latest News
Risk Check: Will Neurogene Inc outperform the market in YEAR2026 Technical Overview & Daily Momentum Trading Reports - baoquankhu1.vn
Published on: 2026-04-11 06:56:54 - baoquankhu1.vn
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL) - The Globe and Mail
Stock Market Recap: Is Neurogene Inc part of any major index2026 Review & Community Trade Idea Sharing Platform - baoquankhu1.vn
Market Wrap: Does Neurogene Inc align with a passive investing strategy2026 Growth vs Value & AI Driven Stock Reports - baoquankhu1.vn
Canaccord Genuity Remains a Buy on Neurogene (NGNE) - The Globe and Mail
Brokerages Set Neurogene Inc. (NASDAQ:NGNE) Price Target at $44.00 - Defense World
Neurogene (NASDAQ:NGNE) Given New $180.00 Price Target at Canaccord Genuity Group - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Institution Moves: Is Neurogene Inc stock risky to hold nowQuarterly Performance Summary & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Neurogene (NGNE) president and CFO Cvijic sells $55k in stock By Investing.com - Investing.com South Africa
Neurogene (NGNE) president and CFO Cvijic sells $55k in stock - Investing.com Canada
Neurogene (NGNE) CFO’s 2,558-share sale tied to mandatory RSU tax withholding - Stock Titan
Neurogene (NGNE) CEO McMinn logs small, tax-related sale after RSU vesting - Stock Titan
RSU tax sale: Neurogene (NGNE) CMO disposes 828 shares - Stock Titan
Pullback Watch: Will Neurogene Inc stock hit new highs in YEARTrade Risk Assessment & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Equities Analysts Set Expectations for Neurogene Q1 Earnings - MarketBeat
Neurogene (NGNE) Receives a Buy from LifeSci Capital - The Globe and Mail
HC Wainwright Weighs in on Neurogene FY2027 Earnings - Defense World
Neurogene (NGNE) price target increased by 37.29% to 82.62 - MSN
Brokers Issue Forecasts for Neurogene FY2027 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Vertex Pharmaceuticals (VRTX) and Sarepta Therapeutics (SRPT) - The Globe and Mail
H.C. Wainwright reiterates Neurogene stock rating at buy, $70 target By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Neurogene stock rating at buy, $70 target - Investing.com
Q1 Earnings Estimate for Neurogene Issued By Lifesci Capital - MarketBeat
Neurogene Advances Rett Gene Therapy Toward BLA With Strong Cash Runway - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Neurogene (NGNE) - The Globe and Mail
Neurogene (NASDAQ:NGNE) Announces Quarterly Earnings Results, Beats Expectations By $0.08 EPS - marketbeat.com
Neurogene: Q4 Earnings Snapshot - theheraldreview.com
Neurogene Reports Positive Interim Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome and Advances Toward Commercialization in 2026 - Minichart
Neurogene Inc. Advances Gene Therapy for Rare Neurological Diseases with EXACT Platform and NGN-401 Clinical Development - Minichart
Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Neurogene 10-K: Revenue $0.0M, EPS $(4.24) on $90.4M net loss - TradingView
Neurogene (NASDAQ: NGNE) details Rett gene therapy progress and cash runway - Stock Titan
William Blair reiterates Neurogene stock rating on trial progress - uk.investing.com
William Blair reiterates Neurogene stock rating on trial progress By Investing.com - Investing.com India
Leerink reiterates Neurogene stock rating on Rett syndrome progress By Investing.com - Investing.com Australia
Leerink reiterates Neurogene stock rating on Rett syndrome progress - Investing.com
Neurogene Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Neurogene : Corporate Presentation March 2026 - marketscreener.com
NGN-401 clinical developments and financials drive Neurogene Inc. corporate update - Traders Union
Neurogene full yr net loss widens on higher R&D costs - TradingView
NGNE: NGN-401 advances with full trial enrollment, FDA Breakthrough status, and strong cash runway - TradingView
Neurogene (NGNE) deepens Rett gene therapy push with 2025 loss and long cash runway - Stock Titan
Neurogene Inc Stock (NGNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):